Details for Patent: 8,957,046
Which drugs does patent 8,957,046 protect, and when does it expire?
Patent 8,957,046 protects VOSEVI and is included in one NDA.
This patent has eighty-nine patent family members in thirty-six countries.
Summary for Patent: 8,957,046
| Title: | Nucleoside phosphoramidate prodrugs |
| Abstract: | Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I. |
| Inventor(s): | Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US14/254,737 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,957,046
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | 8,957,046 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR | ⤷ Start Trial | ||||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | 8,957,046 | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,957,046
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2203462 | ⤷ Start Trial | 214 5029-2014 | Slovakia | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | C300704 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | PA2014040 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2203462 | ⤷ Start Trial | CA 2014 00061 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
